External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer

BACKGROUND: Castration-resistant prostate cancer (CRPC) patients have poor prognoses, and docetaxel (DTX) is among the few treatment options. An accurate risk classification to identify CRPC patient groups for which DTX would be effective is urgently warranted. The Armstrong risk classification (ARC...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Kazuhiko, Komatsu, Kenji, Kubo, Taro, Natsui, Shinsuke, Nukui, Akinori, Kurokawa, Shinsuke, Kobayashi, Minoru, Morita, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997751/
https://www.ncbi.nlm.nih.gov/pubmed/24742323
http://dx.doi.org/10.1186/1471-2490-14-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997751/
https://www.ncbi.nlm.nih.gov/pubmed/24742323
http://dx.doi.org/10.1186/1471-2490-14-31

Ejemplares similares